
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio Inc. has showcased promising advancements in its portfolio, particularly with the introduction of KRRO-121, a subcutaneous RNA editing drug aimed at stabilizing glutamine synthetase and enhancing ammonia clearance in disease conditions. The drug has demonstrated robust liver uptake and improved safety profiles in non-human primates, indicating its potential to address significant unmet medical needs in conditions that could exceed a market potential of $3.5 billion. With an impending IND filing projected for the second half of 2026, coupled with demonstration of up to 40% editing efficacy, Korro Bio is well-positioned to capitalize on its innovative platform for RNA editing, bolstering optimism surrounding its financial prospects.
Bears say
Korro Bio faces significant challenges that contribute to a negative outlook on its stock, primarily due to recent disappointing results from its KRRO-110 AATD program and the introduction of KRRO-121 amid ongoing development risks. Key concerns include potential delays in clinical trials, the failure to produce favorable clinical data from its pipeline candidates, and the possibility of long-term dilution impacting shareholder value. Additionally, the risk of regulatory disagreements over data interpretations and competitive advancements in treatment methods further undermine the company's market positioning and financial stability.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares